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In 2000 the United States launched the National Nanotechnology Initiative and, along with it, a well-defined set of goals for nanomedicine.
This Perspective looks back at the progress made toward those goals, within the context of the changing landscape in biomedicine that has
occurred over the past 15 years, and considers advances that are likely to occur during the next decade. In particular, nanotechnologies for
health-related genomics and single-cell biology, inorganic and organic nanoparticles for biomedicine, and wearable nanotechnologies for
wellness monitoring are briefly covered.
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When rowing a boat across a big lake, you
can paddle for a long time, and the far shore
will continue to appear almost as far away as
when you started. However, when you look
back to your starting point, the amount of
distance traveled can be startling. In 2000,
Neal Lane, then President Clinton’s Science
Advisor, presented the first Implementation
Plan for the US National Nanotechnology
Initiative (NNI) (1). That document laid
out some clear goals for nanomedicine:
i) Rapid, more efficient genome sequencing
enabling a revolution in diagnostics and
therapeutics
ii) Effective and less expensive health care
using remote and in vivo devices
iii) New formulations and routes for drug
delivery that enormously broaden their
therapeutic potential by targeting the de-
livery of new types of medicine to pre-
viously inaccessible sites in the body
iv) More durable rejection-resistant artificial
tissues and organs
v) Devices that enable vision and hearing aids
vi) Sensor systems that detect emerging dis-
ease in the body, which ultimately will shift
the focus of patient care from disease treat-
ment to early detection and prevention.
The goals of the 2000 NNI have largely
stood the test of time and even capture some
of today’s grand challenges in the health sci-
ences. I’ll look back at selected items from
this list and provide brief descriptions of
how far we have come. For most of these
goals, nanotechnologies have played support-
ing, albeit gradually increasing, roles. For
example, any discussion of diagnostics, early
disease detection, and disease prevention
would likely lead with the amazing progress
in the “-omics” fields and the emerging ef-
forts to define “wellness” quantitatively that
ultimately will provide the baseline against
which disease is measured (2). However, a
little digging reveals that nanotech is playing
increasingly important roles in the emerging
generation of omics tools. For other goals,
such as those associated with new formula-
tions and routes for drug delivery, nanotech
has played a major role, even if widespread
clinical applications are still on the horizon.
Just like the rower’s view from the lake, the
various end goals of the NNI are still a ways
off, but the distance covered is impressive.
Although the goals of the 2000 NNI still
appear prescient, there have been major
breakthroughs in medicine and biotechnol-
ogy that weren’t anticipated 15 y ago. For
example, single-cell biology was not really a
field in 2000, but now it is one of the most
rapidly evolving assay biotechnologies, with
potentially disruptive implications in terms
of how we think about biological systems
and how we understand human disease
and health states. As a second example, until
a couple of years ago the idea of harnessing a
patient’s immune system as a powerful anti-
cancer drug was more or less a backwater of
cancer research. Immune checkpoint inhibi-
tors, which now are dominating new cancer
clinical trials, with several recent Food and
Drug Administration approvals, were only
being identified in 2000 (3). However, cancer
immunotherapy (4) in the forms of both
checkpoint inhibitors and cell-based thera-
pies is increasingly altering the dialogue of
“cancer treatments” to “cancer cures.” These
two breakthrough areas relate somewhat to
the Year 2000 NNI goals 1 and 3, respec-
tively, although the supporting roles that
nanotech is playing in the development of
these new fields are quite distinct from those
anticipated 15 y ago.
This paper is a perspective rather than a
proper review, so many topics are necessarily
not covered. Of the six original NNI goals, I
don’t discuss numbers 4 and 5, and progress
toward a couple of the others is mentioned
only briefly. Even for those topics I do dis-
cuss, I am forced to neglect a great deal of
great science, and for that I apologize in ad-
vance! In the following pages I stress both the
fundamental scientific advances that are en-
abling the current state of the art of nano-
medicine and the conceptual advances and
biomedical needs that are driving the field.
In the “bottom-up” spirit of nanotechnology,
I begin with discussions of nanotech contri-
butions to genomics and other -omics mea-
surements, because those measurements are
increasingly providing a foundation for mod-
ern medicine. Finally I briefly peer into the
bright future of nanomedicine.
Genomics and Nanotechnology
Goal no. 1 of the 2000 NNI forecasts an
important role for nanotech in enabling in-
expensive sequencing. The rapid advance-
ment in next-generation genome sequencing
(NGS) technologies has been a triumph of
modern biotechnology, so that the $1000
genome is now a reality (5). In fact, the NGS
tools have advanced to the point that the
technology is effectively a given, and the
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intellectual effort within a genomics study
now is centered on the scientific design and
interpretation of population-based studies
(6). However, NGS has major deficiencies.
First, most NGS methods are limited to short
reads, although alternative technologies are
emerging that permit longer reads (7). An-
alyzing an NGS dataset is, by analogy, similar
to reading a book in which short sentence
fragments are placed in random order rela-
tive to how the text actually was written. To
make it understandable, the book must be
reassembled correctly from those short
fragments. Second, NGS requires amplifica-
tion. This requirement, combined with short
reads, means that the identification of many
natural or disease-associated molecular le-
sions, such as repeat-rich regions, gene am-
plifications and deletions, or chromosomal
translocations, can be challenging. Finally,
NGS requires expensive reagents. Thus,
new sequencing or mapping technologies
are emerging based on long reads of single
DNA molecules, without the need for am-
plification or even reagents (8). These ap-
proaches are enabled by nanotechnologies
(Fig. 1) with specific design parameters that
draw from many years of polymer-based
physics, biophysics, and physical chemistry.
Nanochannel-based single-molecule ge-
nome mapping (Fig. 1A) (9) is used to help
assemble genomes and fill in information
gaps that are not captured by NGS. The or-
igins of the technique were methods in which
single DNA molecules, 102–104 kb long, were
stretched out on a microscope slide and
cleaved using site-specific enzymes. In this
way a 400-kb DNA molecule might be cut
into 20–40 components (10). The physical
length of the resulting segments, averaged
over many DNA molecules similarly ana-
lyzed, provided a crude genome map (11).
For nanochannels, the concept illustrated in
Fig. 1A relies on fluorophores that are in-
troduced by using nicking endonucleases that
cut the dsDNA at specific restriction sites.
These locations provide a map that includes
deletions, amplifications, and translocations
and provides guides for NGS genome as-
sembly. Of course, many physical chemistry
issues, such as the interplay of the persistence
length of the DNA molecules, the ionic
strength of the solvent, the conditions for
uncoiling the DNA, and the dimensions of
the nanochannel, have all provided a scientific
foundation for this nanotechnology (12, 13).
Long, accurate sequencing reads of un-
amplified DNA would negate the need for
mapping. Nanopore-based sequencing (14) is
such a method, although it has been technically
challenging to develop and only very recently
has permitted some sequence determination of
an actual genome (15, 16) The basic idea dates
back some 20 y and draws from fundamental
work in surface science, molecular biology,
nanofabrication, and electrochemistry (17). In
one manifestation, two aqueous electrolyte so-
lutions are connected through a single protein
nanopore, such as such as Mycobacterium
smegmatis porin A (MspA). A bias is applied,
and current is measured as DNA is drawn
through a bilayer-entrained pore protein at a
rate that is controlled through the use of mo-
lecular motors such as Φ 29 DNA polymerase
(DNAP) (18). A variant developed by Pacific
Biosciences (19) is shown in Fig. 1B. Four
distinct fluorophores are used to read out the
action of the polymerase, which is isolated
within a nanofabricated waveguide. The poly-
merase, which also is used for whole-genome
amplification, permits long, relatively unbiased
reads. Each polymerase permits a read rate of
about four to five bases per minute, with
thousands of single polymerases in nano-
waveguides used in parallel. A third variant,
which was released by Oxford Nanopore
Technologies as the MinION nanopore se-
quencing product, is about the size of a USB
memory stick. Early literature reports on the
MinION imply that it may not yet be ready
for wholesale sequencing (20), but it does
have some compelling applications (21).
Although genomics has led the -omics rev-
olution, nanotechnologies (and microfluidics)
are playing increasingly important roles in re-
ducing -omics technologies to the level of a
single cell, and I turn to this area next.
Single-Cell -Omics in Biology and
Biomedicine
Single-cell biology holds the promise of
unraveling the heterogeneity that often
confounds the interpretation of biological
or biomedical measurements. For example,
single-cell analysis is increasingly applied
toward understanding immune responses
triggered during various cancer immuno-
therapies (22–25) or for unraveling the
functional behaviors that emerge from het-
erogeneous healthy or diseased tissues (26,
27). Aside from flow- and mass-cytometry
methods (28, 29), virtually every single-cell
-omics platform involves some level of
microfluidics and/or nanotech. Specifically,
a single cell has only a certain number of
copies of any given analyte. By isolating a
single cell within a nanoliter or subnano-
liter volume, those copy numbers can cor-
respond to detectable concentrations, and the
concentrations of contaminants are minimized.
Fig. 1. Nanotechnologies for genome mapping and genome sequencing. (A) Nanochannel-based genome
mapping. (i) The microchip is designed to untangle the DNA and guide long fragments into nanochannels with
diameters <100 nm. (ii) The DNA fragments are fluorescently labeled at specific sites to provide a spatial map of
those sites. (iii) Different fragments are lined up according to the spatially resolved fluorescent signatures to
provide the genome map, shown here for a 300-kb segment. Adapted from ref. 9, with permission from Mac-
millan Publishers Ltd: Nature Biotechnology, copyright 2012. (B) The Pacific Biosciences nanopore-based genome-
sequencing platform, in which single-molecule, real-time sequencing data are obtained from a DNA polymerase
that is isolatedwithin a 100-nm-diameter pore in an aluminum film. (i) The pore serves as a zeromodewaveguide
for optical analysis of uninterrupted template-directed DNA synthesis using four distinguishable fluorescently
labeled dNTPs. (ii) The temporal order of enzymatic incorporation of the dNTPs into a growing DNA strand is
illustrated. At each step a fluorescent dNTP is incorporated, generating a fluorescent signal that is collected ef-
ficiently within the nanowaveguide. The fluorophore then is cleaved and diffuses out of the waveguide. (iii) An
optical readout for a single channel is illustrated. Reproduced from ref. 19, with permission from AAAS.
















Microchip methods also can uniquely permit
analysis of very small tissue samples.
Single-cell methods have been reviewed
recently (30–32), so only a general technol-
ogy overview plus a brief discussion of what
is learned uniquely through single-cell assays
is given here. Single cells are, from a physico-
chemical point of view, finite systems. That
is, quantitative measurements of transcripts,
proteins, metabolites, and so forth in different
single cells will yield different copy numbers of
those analytes. Thus, the most useful single-
cell methods are designed to assay a panel of
analytes from statistically significant numbers
of single cells. Added value that is uniquely
provided by such single-cell analyses includes
• Histograms of the abundance distributions
of a given analyte across a population of cells
help define outliers, such as cells that over-
express a particular protein. This information
can be particularly important for immunol-
ogy applications (23, 33). For certain analytes,
the abundance distributions also may be
interpreted as the fluctuations of the cell (sim-
ilar to positional fluctuations in a Brownian
particle), thus providing a bridge to statistical
thermodynamics models (34).
• Correlations (and anticorrelations) between
the measured analytes are statistical relation-
ships that provide important clues regarding
the structure of gene or protein signaling
networks and how that structure is altered
by some perturbation (28, 35–37). Correla-
tions derived from single-cell assays are not
the same as those derived from bulk assays.
In a bulk assay, the average levels of two ana-
lytes may both be repressed by a drug and
thus exhibit correlated behavior. For single-
cell analyses, statistical correlations between
any two analytes are determined through an
x,y scatter plot of the assayed values for each
single cell. The average analyte abundance is
not a factor in such plots (Fig. 2A).
• Detailed lineage tracing is enabled, permit-
ting diseased tissues or cells to be traced
back to the originating healthy tissue or cell
types (26, 38) or circulating tumor cells to be
traced back to the originating lesion (39).
• Some recent studies capture multiple levels
of biological information (i.e., proteins and
metabolites) from the same single cells
(Fig. 2A). Such studies have many applica-
tions, ranging from associating a particular
T-cell receptor gene with a T-cell antigen
(22, 25) to associating the functional be-
haviors of cells [e.g., cellular motility (40)
and glycolytic rate (41), among others]
with genetics, drug response, and so forth.
• Several platforms permit an -omics analysis
of defined cell populations (i.e., zero, one,
two, three, or more cells). Such platforms
provide unique insights into cellular behav-
iors, such as how pairwise cell interactions
influence bulk cellular architectures or quan-
titative analysis of immune cell–disease cell
interactions (36, 42–44).
• A technologically distinct class of micro-
chip designs permits individual cells to be
isolated within droplets with a volume 0.05 pL
to 1 nL (45, 46), and those droplets are en-
trained within a fluidic flow that can be cou-
pled with an optical analysis platform (Fig.
2B) (47, 48). The chemical composition of
individual droplets can be manipulated to
permit rapid and high-throughput screen-
ing assays. Applications related to screening
antimicrobial or antiviral agents or for var-
ious binding assays have been reported with
very significant throughput advantages over
traditional assays. For a technique known as
Drop-seq, individual cells are similarly en-
trained within nanodrops on microfluidic
chips. Each droplet also contains a micro-
particle that is encoded with a unique DNA
barcode address. Cells are lysed within the
droplet, the mRNAs are captured on the
barcoded microbead, and then all micro-
beads are analyzed in parallel. The bar-
code address allows the transcriptome
analysis to be reassociated with individual
cells (49). A related molecular barcoding
microwell transcriptomics approach was re-
cently reported by Fan et al. (50)
Most single-cell analysis tools, aside from
cytometry methods, are young and so are
only now being commercialized.
Inorganic Nanoparticles and Related
Nanomaterials in Biomedicine
Metal nanoparticles (NPs) (51) and semi-
conductor quantum dots (QDs) (52, 53) and
related materials, such as single-wall carbon
nanotubes (SWNTs) (54, 55), are increas-
ingly used for preclinical in vitro and in vivo
(imaging) diagnostics (56–58). Therapeutic
applications have been slower to develop
(59). The basic concept is that the size, shape,
and composition of the inorganic core pro-
vide a useful physical property that enables
a colorimetric, electrochemical, Raman, or
other class of assays. The NP surface
chemistry is tailored for the specific assay,
including biomolecular recognition, solu-
bility, and other characteristics that translate
into a very large matrix of materials prop-
erties. For in vitro applications, there is sub-
stantial flexibility in exploiting this matrix.
For in vivo applications, the task is much
Fig. 2. Microfluidics and nanotech tools for single-cell analysis. (A) Illustration of a single-cell barcode chip
(SCBC) in which individual cells are isolated within nanoliter or smaller volume microchambers within a
microfluidics chip mounted on a microscope slide. The glass slide is patterned with a high-density barcode for
protein and/or metabolite assays from isolated single cells. Cells are lysed using the valved microchamber
structure shown in themiddle drawing, and the contents are captured on specific locations within the barcode
array. The fluorescence intensities of the developed barcode stripes are related to calibration curves to yield
the level of the specific analytes. (B) Sample of single-cell data taken on an SCBC. (i) The scatter plot shows the
correlated levels of two phosphoproteins as measured from single cells (red dots) or zero-cell chambers (blue
dots). (ii) A protein–protein correlation matrix from a multiplex SCBC protein and metabolite assay. Adapted
from ref. 41. (C) An illustration of a microfluidics platform for building a regular array of single cells within
nanoliter droplets of water, entrained in oil. The optical micrograph is reproduced from ref. 45, with per-
mission from The Royal Society of Chemistry. The drawing illustrates some of the flexible design parameters
that are used in this type of high-throughput assay. Cells can be probed with antibodies, viruses, mRNA-
encoded beads, NPs, and so forth for a controllable amount of time, using a delay line or related method. Cells
may be interrogated optically and sorted or otherwise analyzed at the protein, transcript, or functional level.
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more challenging. Each of the elements of
this properties matrix [which includes the
Stokes radius, the surface charge (60, 61),
the density of surface chemical groups (62,
63), and the elastic modulus (64), among
others] can strongly influence in vivo phar-
macokinetics (PK) (i.e., circulation times,
uptake within specific cells or within spe-
cific organs or disease sites, clearance route,
and toxicology) (65, 66). In particular, un-
derstanding which basic properties of
nanomaterials can lead to nonspecific and
potentially harmful biological interactions
(67–69) in vivo is a very active field of
study. In any case, this matrix of materials
properties for optimization represents a
sort of “opportunity hurricane” for the
scientist or engineer. Efforts to elucidate
how best to optimize NPs for specific tasks
comprise much of the basic science of these
NPs. Organizations such as the National
Cancer Institute’s Nanotechnology Char-
acterization Laboratory have played impor-
tant roles in guiding such efforts (70).
Although approved clinical applications are
beginning to appear, the bulk of the science
is still maturing through mouse model stud-
ies. In following paragraphs, I provide a very
brief overview of this underlying science and
highlight illustrative examples in Figs. 3 and 4.
Noble-metal NPs have been used for sev-
eral years for the point-of-care detection
of blood-based biomarkers from droplets
of blood; gold NPs provide the colorimetric
agents for analyte detection. The basic
exploited physical property is the surface
plasmon resonance (SPR), which is in the
visible or near-visible part of the spectrum
for noble-metal NPs. The SPR is a collective
resonance that carries a very high oscillator
strength, with a peak wavelength, line shape,
and intensity that strongly depend upon NP
size, shape, and local dielectric environment.
The basic optical properties of colloidal gold
were described more than 100 y ago by
Mie using Maxwell’s equations (71). Cur-
rent models can capture the remarkable
linear and nonlinear (72) optical proper-
ties achievable through modern synthetic
methods in which surface chemistry, local
chemical environment (73), and NP size
and shape (74) are controlled. For in vitro
biological applications, synthetic methods
for surface-loading high-density coverages
of DNA have enabled efficient cell delivery
for various in-cell, live-cell assays (Fig. 3)
(75). Other surface chemistries have en-
abled a myriad of electrochemical, chem-
ical, and optical platforms for sensing and
in vitro diagnostics (76–78). For in vivo
applications, that synthetic control has been
harnessed for minimizing toxicity [exhibited
by some very small gold NPs (79)] and for
targeting delivery of gold nanorods to spe-
cific tissues (80). Gold nanorods have shown
promise in animal models for photothermal
therapy applications. In such a therapy (81),
the particles are delivered to the disease site,
and laser light is used to penetrate into the
tissue, excite the NPs, and transfer thermal
energy to—and thus kill—the diseased tissue.
This concept has had only limited success
in human trials (82) and so may need more
time to mature.
Remarkable advances in nanomaterials
synthesis have occurred for a broad variety
of NPs, including magnetic NPs (83, 84).
These advances have enabled applications of
ferromagnetic and superparamagnetic NPs
for both in vitro and in vivo (imaging) di-
agnostic assays (85, 86). For in vitro assays,
biofunctionalized magnetic NPs have a his-
tory of use for magnet-assisted cell sorting.
A recent variant of that application is the
use of antibody-coated magnetic NPs for
detecting (using a custom-built microchip-
NMR tool) and sorting microvesicles re-
leased by certain solid tumors (87). Micro-
vesicles are 10- to 100-fold smaller than the
tumor cells from which they are released but
can carry many of the biomarkers that iden-
tify the originating cell as a diseased cell (88).
For certain tumors, such as glioblastomas,
microvesicles are released into the blood,
although circulating tumor cells are not.
Fig. 4 illustrates two in vivo live-animal
imaging applications of highly fluorescent
semiconductor QDs (Fig. 4A) (89) and near-
IR fluorescing SWNTs (Fig. 4B) (90). In both
cases, the nanomaterial exhibits a compelling
optical property that enables the imaging
application and also is highly engineered,
through surface chemistry control, for useful
PK and pharmacodynamics (PD) properties.
Fig. 3. The gold NP-based nanoflare construct is
used for detecting specific mRNAs in live cells. The
gold NPs are coated with a dense layer of DNA,
which promotes cell penetration. The DNA shown
comprises a fluorescent reporter (the Cy5 flare),
which is nonfluorescent when bound to the Au NP.
This nanoflare is hybridized with an antisense DNA.
When the nanoflare encounters the target mRNA,
the flare is released, thus activating fluorescence
within the cell and permitting live-cell sorting based
on the expression of a specific gene. Adapted from
ref. 75.
Fig. 4. Semiconductor QD and SWNT in vivo imaging probes. (A) Semiconductor QD imaging of stem
cells in bone marrow. (i) Polyimidazole incorporating norbornene provides a bio-compatible surface
functionalization for highly luminescent semiconductor core-shell QDs as well as a chemical handle for
preparing QD–antibody conjugates, as shown (not to scale). Lyscine (amine-presenting) residues on the
antibody are highlighted in red. The QD–antibody particles exhibit a moderate negative surface charge,
which is generally favorable for improved in vivo circulation. (ii) Use of the QD–antibody particles as
in vivo imaging probes for single-cell imaging in the bone marrow of a live murine model, viewed
through a calvarial window. The arrow points to single Sca-1+c-Kit+ cell, which is a late-stage hemato-
poietic stem cell. The red and green cells represent Sca-1+ and c-Kit+ cells, respectively. Adapted from
ref. 89. (B) Polymer-stabilized SWNTs used as in vivo near-infrared (NIR) fluorescent probes of vasculature.
(i) Near-IR fluorescence of mouse vasculature. (ii) Fluorescence intensity taken along the dashed green line
drawn on the image in i is plotted and reveals an imaging resolution of a few tens of micrometers. Adapted
from ref. 90, with permission from Macmillan Publishers Ltd: Nature Medicine, copyright 2012.
















These types of probes, although not yet
clinical tools, are providing powerful ap-
proaches for preclinical investigations.
Organic Nanoparticles for Drug Delivery
Goal no. 3 of the 2000 NNI, which describes
the promise of NP drug-delivery systems, was
largely inspired by the promising perfor-
mance of liposomal delivery vehicles (91), at
least four of which had received approval
(one from outside the United States) before
2000 (92, 93). Liposomes are spherical vesi-
cles with at least one lipid bilayer and can be
used to carry hydrophobic drug molecules
that associate within the membrane or hy-
drophilic molecules that are trapped in the
core. The approval of the protein-drug con-
jugate Abraxane (94) in 2005 gave further
impetus to the field.
Nanotherapeutics such as liposomes are
based on a concept in which many copies of
a drug molecule are loaded into a delivery
vehicle (the NP) that is optimized for im-
proved PK and PD relative to the drug by
itself. Nanotherapeutics have broad applica-
tions for many disease conditions; their use
in oncology illustrates their general value
(59). For almost all metastatic cancers, the
frontline molecular treatments are small-
molecule chemotherapies. High systemic ex-
posure of patients to those drugs frequently
leads to dose-limiting toxicity. The nature of
small-molecule drugs is that they exhibit
short (<1 h) circulation times and indis-
criminate tissue penetration, thus affecting
both healthy and diseased tissue with a PK
and PD profile that is defined largely by the
nature of the drug rather than the needs of
the patient. Early work on polymer–drug
conjugates showed that large-molecular-weight
particles, or macromolecules, could avoid such
rapid clearance and, in fact, accumulate in
tumor sites over a period of many hours (95,
96). This effect became known as the “en-
hanced permeability and retention” (EPR) ef-
fect. EPR is not a general characteristic of all
nanotherapeutics; early liposomal formulations
were found to clear rapidly from the blood and
often to accumulate in the liver. The variations
in PK and PD across different formulations
suggested the compelling bioengineering chal-
lenge that drives the current science and
translational progress in the field.
Organic nanotherapeutics under develop-
ment today include liposomes with single or
multiple bilayered membrane structures built
from natural or synthetic lipids (97), dendrimer
constructs, albumin-bound formulations (94),
and polymeric nanoparticles engineered from
biocompatible and biodegradable polymers.
A common theme across these systems is
that the NP delivery vehicle itself contains the
engineering handles for controlling the drug
PK and PD. These handles include ligands
for tumor targeting (98) and mechanisms for
triggered drug release based on pH (99) or
enzymatic signals (100) as well as molecular
or nanofabrication engineering to control
surface charge (zeta potential), NP size, NP
shape (101), and NP elastic modulus (102).
Of course, as with inorganic NPs, the avail-
able design space is vast. A measure of
progress in this field is the rapidly increasing
number of NP formulations that have ad-
vanced into Phase I–III clinical trials (92).
In Figs. 5 and 6 I highlight two very dif-
ferent examples of organic NP preparations
that reflect unique aspects of the state of the
art and which are being translated through
human trials. Fig. 5 illustrates the use of the
particle replication in nonwetting templates
(PRINT) technology, developed by DeSimone’s
group (102). This example highlights the role
that the particle modulus can play in organ
delivery. The highly versatile PRINT technol-
ogy has been used to prepare NP vaccines that
have been translated into an initial Phase I/IIa
clinical trial for influenza (103).
Fig. 6 illustrates the use of polycyclodextrin
(poly-CD) NPs as tumor-targeting delivery
agents for siRNA therapies. In the example, a
human transferrin (TF) protein-targeting li-
gand provides the NP with tumor-targeting
characteristics. This NP was translated
into a Phase I clinical trial for melanoma
cancer patients. Tumor biopsies, collected
after therapy, revealed that the NPs local-
ized to the tumor (Fig. 6B) and successfully
repressed the levels of the target protein in
the tumor cells (104). Related NP formulations
Fig. 5. Illustration of the PRINT method for making nano- and microparticles. (A) PRINT uses the micro- and
nanolithography fabrication tools of the semiconductor industry to build molds (shown in green). These are
coupled with roll-to-roll processing to prepare size- and shape-controlled particles that then are released
from the molds. Different polymer and hydrogel chemistries are used to control the chemical and physical
properties of those particles. (B and C) Two batches of fluorescent hydrogel microparticles are prepared with
different elastic moduli, based on the extent of cross-linking (10% in B; 1% in C). The particles with the
lowest cross-linking have elastic moduli designed to emulate that of a red blood cell. (D) Illustration of the
organ distribution of the PRINT particles with high and low numbers of elastic moduli 2 h after tail injection
into a mouse. Adapted from ref. 102. The particles illustrated here are being investigated, in a preclinical
setting, as a component of synthetic blood.
Fig. 6. A polymer-based 70-nm nanotherapeutic for
siRNA delivery in humans. (A) Cyclodextran (CD) forms
a conical binding pocket for the supramolecular as-
sembly of adamantane (AD). A poly-CD oligomer has
several such binding pockets, which can be used for
the assembly of adamantane-labeled drugs or, in the
example shown, TF ligands that can target cancer cells.
When poly-CD is combined with adamantane-labeled
TF and siRNA, the TF is presented on the surface of
the NP, and the siRNA is localized within the hy-
drophilic interior, thus providing directed delivery
of the siRNA to cancer cells. The nanotherapeutic is
administered to patients intravenously. (B) Data from
a clinical trial on melanoma cancer patients. Five-
nanometer adamantane-labeled gold NPs (Au-PEG-
AD) are used for tissue labeling of the poly-CD NPs.
The three images show that the NPs (green color in left
image) are not in the skin (s) or the epidermis (epi) but
instead are localized within the tumor (t). Adapted
from ref. 104, with permission from Macmillan Pub-
lishers Ltd, Nature, copyright 2012. Related poly-CD
nanotherapeutics are being tested in several clinical
trials for various cancer indications.
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serving as carriers of the chemotherapeutic
camptothecin are being explored currently
in a number of human trials (92).
Nanomechanical and Nanoelectronic
Devices and Wellness Monitoring
Goals nos. 2 and 6 of the 2000 NNI, which
emphasized remote sensor systems and
in vivo devices for early disease detection and
diagnosis, represented interrelated grand
challenges with somewhat similar roadmaps
to success. Recent influences on these goals
are the proliferation of smart phones and
other smart devices as well as the emerging
emphasis on wellness (105). A relevant
emerging wellness trend is that an individual
is provided with regular measurements of
his/her health status. The individual can
make lifestyle, exercise, and diet adjustments
informed by those measurements so as to
maximize health benefit. The technology
challenge is to provide accurate, informative,
and readily interpretable diagnostic mea-
surements at low cost. The emerging science
and technology of wearable health monitor-
ing devices illustrates a dominant approach
toward meeting this challenge. Nanotech
does not play a role in the early-stage ex-
amples of such wearable devices, although it
is clear that nanotech will play important
roles in the near future. Current smart devices
monitor a panel of basic body functions, such
as heart rate, body temperature, and exer-
cise but, with few exceptions (106), do not
monitor specific biomarker analytes. This
current functionality is enabled by a menu of
microelectromechanical machines (MEMs)
such as microphones, accelerometers, and
gyroscopes. The uptake of MEMs in con-
sumer products was young in 2000, but of
the three waves of proliferation initially
envisioned for MEMs—automotive, con-
sumer electronics, and home integration—
the first two are now considered complete
(107). A fourth wave, relevant to this dis-
cussion, is likely personal integration.
Recent advances (108–115) in integrating
electronics onto low-elastic modulus polymer
substrates and other moldable materials that
are conformal, biocompatible, and, in some
instances, even self-powered (116) are open-
ing up a large menu of wearable devices based
on mechanical, electronic, or electrochemical
signal transduction (117, 118). A large frac-
tion of these devices contain some nanotech-
nology, with a scientific basis that can be
traced back to early demonstrations of nano-
tube (119) or nanowire (120, 121) sensors and
the integration of nanowires and nanotubes
onto plastic substrates (122, 123). The net
result is that biomarker-rich liquids, such as
sweat or saliva (124), can be used for contin-
uous multiplex monitoring of health status-
relevant analytes. An example of a nanotech-
enabled tooth “decal” sensor is shown in Fig.
7. This device straddles the line between an
implant and a wearable device. Although the
presented data are from a benchtop experi-
ment, they clearly illustrate the potential for
real-time monitoring of both bodily functions
(breathing) and analytes (bacteria in saliva).
Concluding Remarks: Nanomedicine and
Emerging Challenges
In this Perspective, I have provided a partial
view of the state of the art of nanomedicine.
Unlike applications in fields such as energy
or non–health-related biotech, biomedicine
has a unique and justifiably conservative set
of rules for adopting new technologies for
human use. Witness, for example, the re-
markably rapid rise of CRISPR genome-
editing technologies (and associated biotech
companies) over the past 2 y. Witness also,
however, the healthy scientific debate (125)
and public (126) controversy that emerged
when gene editing was carried out on non-
viable human embryos (127). This response
was warranted, but it means that gene-edit-
ing technologies have a long road to travel
from the benchtop to the bedside. Nano-
medicine faced similar challenges 15–20 y
ago. It was a brand-new field, and the ability
to tune physical or PK properties by tuning
NP size and shape was a sparkling new ad-
dition to the synthetic toolkit. However, that
addition was not well understood, and cur-
rent good manufacturing practice (cGMP)-
type manufacturing, which is a critical first
step toward human health applications, was
virtually unknown in nanotech. In addition,
there were challenges unique to the field. The
pool of young scientific talent that could
work across the disciplines of chemistry,
physics, materials science, engineering, and
biomedicine didn’t exist, and most research
institutions didn’t have the infrastructure to
support that talent. All these challenges have
been fully or partially addressed over the past
15 y. The number of nanotechnologies that
currently are undergoing some level of human
testing and the several areas in medicine in
which nanotech is providing unique solutions
are important measures of that success. Al-
though the impact of this progress on the
human health condition is still marginal, it will
be felt increasingly over the next decade. Thus,
as we look back at the distance traveled, it is
indeed startling to find how far we have come.
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